GARCIA PETER S
Known title: Chief Financial OfficerCIK: 0001188956
GARCIA PETER S's purchase track record
GARCIA PETER S has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/13/2024 | ALXO | $102K | -74.6% | -83.2% | +11.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALXO | ▼ Sell | Tax Withholding | 761 | $2K | 8/14/2024 | View on chart |
| ALXO | ▼ Sell | Tax Withholding | 1,789 | $11K | 6/28/2024 | View on chart |
| ALXO | ▲ Buy | Open Market | 12,000 | $102K | 6/13/2024 | View on chart |
| ALXO | ▲ Buy | Grant | 25,000 | $0 | 2/14/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,893 | $28K | 12/29/2023 | View on chart |
| ALXO | ▲ Buy | Grant | 32,000 | $0 | 7/25/2023 | View on chart |
| ALXO | ▼ Sell | Open Market | 887 | $7K | 6/30/2023 | View on chart |
| ALXO | ▼ Sell | Open Market | 893 | $10K | 12/29/2022 | View on chart |
| ALXO | ▲ Buy | Grant | 29,000 | $0 | 8/5/2022 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 6,637 | $27K | 2/7/2022 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 8,363 | $40K | 2/7/2022 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 7,229 | $29K | 10/18/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,851 | $155K | 10/18/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,903 | $105K | 10/18/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,437 | $81K | 10/18/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 411 | $24K | 10/18/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 438 | $26K | 10/18/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 189 | $11K | 10/18/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 7,199 | $566K | 9/17/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,100 | $89K | 9/17/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,746 | $139K | 9/17/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 273 | $22K | 9/17/2021 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 11,345 | $46K | 9/17/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,027 | $80K | 9/17/2021 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 1,426 | $6K | 9/16/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,426 | $115K | 9/16/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 35 | $3K | 8/23/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 19,448 | $1.5M | 8/23/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 10,743 | $813K | 8/23/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,616 | $201K | 8/23/2021 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 60,000 | $245K | 8/23/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,593 | $113K | 8/23/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 3,497 | $252K | 8/23/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 18,060 | $1.3M | 8/23/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 4,008 | $295K | 8/23/2021 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 10,000 | $41K | 8/17/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 4,687 | $306K | 8/17/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,368 | $156K | 8/17/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 505 | $34K | 8/17/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,400 | $164K | 8/17/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 40 | $3K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
ALX Oncology reports positive Phase 2 data for evorpacept
ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.
ALX Oncology reports positive Phase 2 data for evorpacept. ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.